Clinical trials: Nonalcoholic Steatohepatitis
Hepatocellular Carcinoma
Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease
Global prevalence of Non Alcoholic Fatty Liver Diseases (NAFLD) ranges from 22% to 28%.The spectrum of these hepatic abnormalities extends from isolated steatosis to steatohepatitis (Non Alcoholic Steato-Hepatitis, NASH) and…
- Trial name
- CHALNA (NCT03307408)
- Testing
- blood collection
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
- Trial name
- NCT05039450
- Testing
- EFX
- Where
- 49 sites in United States, Mexico and 1 more
- Volunteers
- 213 people
- Sponsor
- Akero Therapeutics, Inc
Non-alcoholic Steatohepatitis
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.
- Trial name
- NCT05848440
- Testing
- AZD9550
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
NASH - Nonalcoholic Steatohepatitis
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
The aim of this proposal is to investigate a novel imaging method to identify patients with non-alcoholic steatohepatitis (NASH) who are at risk for hepatocellular carcinoma (HCC).
- Trial name
- NCT05165446
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Natalie Torok
Non-alcoholic Steatohepatitis (NASH)
Endoscopic Bariatric Therapy in NASH Cirrhosis
Non-alcoholic steatohepatitis (NASH) is a growing public health problem that affects more than 5% of the population and can lead to cirrhosis and hepatocellular carcinoma.
- Trial name
- ETHIC (NCT04281303)
- Testing
- Endoscopic vertical gastroplasty
- Volunteers
- 10 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Non-Alcoholic Fatty Liver Disease
Functional Roll for Non-alcoholic Fatty Liver Disease
Background: Low physical activity and poor eating habits (incl. high fat and carbohydrates but low fiber intake) are the main reason of obesity epidemic in western societies.
- Trial name
- NAFLDroll (NCT04520724)
- Testing
- plant fiber, maltodextrin bar
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Pomeranian Medical University Szczecin
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Non-alcoholic Fatty Liver Disease (NAFLD), Omega-3 Supplementation
Effectiveness of Nutrition Education Program and Omega-3 Supplementation Among Non-alcoholic Fatty Liver Disease Patients
The aim of this clinical trial is to examine the impact of nutritional education and omega-3 supplementation in influencing body weight, liver enzyme levels, and lipid profiles in patients diagnosed with non-alcoholic fatty liver…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Omega-3 Supplementation, Nutrition Education Program
- Trial name
- NCT06627114
- Testing
- nutrition education program, Omega 3 fatty acids, control group
- Where
- Iraq
- Volunteers
- 159 people
- Sponsor
- Hawler Medical University
Hepatitis
Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance.
- Trial name
- NCT00063232
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-alcoholic Fatty Liver Disease, Liver Fibrosis
Early Detection of Advanced Fatty Liver Disease
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the western world, affecting one in every three subjects.
- Trial name
- NCT03608748
- Where
- Israel
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
The Liver Health Study for Patients with NAFLD
The study will investigate whether the level of fat stored in the liver is related to the liver's ability to burn fat.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
- Trial name
- NCT03151798
- Testing
- Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- University of Missouri-Columbia
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
The Olmsted NAFLD Epidemiology Study (TONES)
Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate…
- Trial name
- NCT04365855
- Testing
- Magnetic Resonance Elastography, Blood draw, Liver biopsy
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Mayo Clinic
Non-alcoholic Fatty Liver Disease
Serine Supplementation for Obese Subjects With Fatty Liver Disease
In this study, the investigators aim to increase the liver tissue level of GSH in NAFLD patients by short-term dietary serine supplementation and improve their liver function by lowering the oxidative stress resulting from…
- Trial name
- NCT02599038
- Testing
- Serine supplementation
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Hanns-Ulrich Marschall
Non-alcoholic Fatty Liver Disease, Evidence of Liver Transplantation
Quantifying Steatosis in Liver Transplant Donors
Non-alcoholic fatty liver disease is the most common chronic liver disease in Hong Kong. Its presence among donors of living donor liver transplants could affect the outcomes of recipients of liver transplantation.
- Trial name
- NCT02579408
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
Non Alcoholic Steatohepatitis
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT03377140
- Testing
- Hesperidin, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
NAFLD
Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease Patients
Non-alcoholic fatty liver disease (NAFLD) includes a wide range of disorders that consist of simple fatty infiltration, steatohepatitis (NASH), and end-stage liver disease (cirrhosis).
- Trial name
- NAFLD (NCT04834063)
- Testing
- Serum Zinc a level, serum selenium level, Fibroscan measurement
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Nonalcoholic Steatohepatitis
Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.
- Trial name
- NCT04216693
- Testing
- Digoxin tablet
- Where
- China
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot Study
The main aim of the study is to determine if an oral supplementation of the LCS has a beneficial effect by itself or even enhances the beneficial effects of a moderate life-style intervention on the progression of NAFLD in humans.
- Trial name
- NucesNASH (NCT02366052)
- Testing
- Nutritional Counseling, Lactobacillus casei shirota (LCS), Nutritional Counseling and LCS
- Where
- 2 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Johannes Gutenberg University Mainz
Non-Alcoholic Fatty Liver Disease
Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.
Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.
- Trial name
- NCT05106049
- Testing
- serum Adiponectin
- Volunteers
- 90 people
- Sponsor
- Assiut University
MAFLD, Fatty Liver
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.
- Conditions
- MAFLD, Fatty Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic
- Trial name
- GL-MAFLD-NFR2 (NCT07564947)
- Testing
- Ganoderma lucidum
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- University of Agriculture, Peshawar
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.